Nanopore promethion 2 solo and consumables.
Active Purchase Order Awarded Last action
- Contract number
- 75F40124P00453
- Awardee
-
Oxford Nanopore Technologies, Inc. UEI FM6MMNBM2TQ5
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $79,465
Award facts
- Opportunity
-
- Amendment Two: Lease of an add-on device capable of long-read length sequencing compatible with Oxford NanoPore GridION and purchase of consumables Solicitation · 75F40124Q00318 · Posted Jul 19, 2024
- Contract value 27% obligated
-
- $79,465.00 Current, with exercised options
- $295,137.00 Potential, with all options
- Completion date 51% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 334516 Analytical Laboratory Instrument Manufacturing
- PSC
- 6640 Laboratory Equipment And Supplies
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Laurel, MD, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $30,112 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $49,353 |
About this award
The U.S. Food and Drug Administration awarded a firm fixed-price purchase order valued at $295,137 to Oxford Nanopore Technologies Inc. for the lease of a PromethION 2 Solo long-read sequencing instrument and associated consumables. The award, announced on September 18, 2024, supports the FDA's research initiatives at its Laurel, Maryland facility, specifically addressing the safety assessment of gene editing technologies in food and drug-producing animals and multiple studies conducted by the Division of Emerging Technologies. The contract structure includes a 12-month base period with four optional 12-month renewal periods, extending through November 2028, with the vendor required to deliver the instrument within 60 days of award and provide scheduled consumable deliveries throughout the contract term.
Oxford Nanopore Technologies Inc., a foreign-owned biotechnology company specializing in nanopore-based genomic sequencing platforms, was selected through a full and open competition Request for Quote process that concluded on August 29, 2024. The company maintains an established track record supplying advanced sequencing technologies to multiple federal agencies, including the National Institutes of Health, Centers for Disease Control and Prevention, and U.S. Department of Agriculture. This award carries no set-aside designation and represents part of the vendor's broader engagement with the federal government in supporting critical research in genomic sequencing applications.
Quick answers
Who was awarded contract 75F40124P00453?
75F40124P00453 was awarded to Oxford Nanopore Technologies, Inc. by Food and Drug Administration (Department of Health and Human Services) on September 18, 2024.
How much is contract 75F40124P00453 worth?
The government has obligated $79,465 on 75F40124P00453. Its potential value, with all options, is $295,137.
Was contract 75F40124P00453 competed?
The extent of competition for 75F40124P00453 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award